2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1452 Wildtype Nup98 cooperates with pre-existing Dnmt3a and Npm1 mutations to accelerate the development of acute myeloid leukemia (AML) in mouse models

Michael Harris Kramer, MD PhD, Stephanie N Richardson2, Nichole Helton, MS3, Daniel R. George, BA4, Sai Mukund Ramakrishnan, MS5, Christopher A. Miller, PhD6, Timothy Ley, MD7
1 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
2 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
3 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
4 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
5 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
6 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
7 Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States
NUP98 is a nuclear pore protein, and also can act as a component of transcriptional complexes in the nucleus. In acute myeloid leukemia (AML), NUP98 is a recurrent fusion partner, with NUP98-fusions present in 1-2% of patients. NPM1 is a commonly mutated gene in AML, present in 25-30% of patients, with the canonical mutation called NPM1c. Data generated by others using human AML cell lines suggest that wildtype NUP98 protein may cooperate with mutant NPM1c to drive expression of HOX genes, acting as a cofactor for oncogenic transcription. Whether these genes cooperate in vivo, and/or whether the expression level of NUP98 can influence its oncogenic effects, is unknown. In this study, a fortuitous observation in a well-established mouse model has helped address these questions.

Mice with hematopoietic-specific mutations in Dnmt3aR878H/+ and Npm1cA/+ serve as a model of AML, with nearly all individuals developing AML in 6-15 months (Loberg et al., 2019). In a recent study, we characterized 11 murine AMLs (mAMLs) developing in this model with whole genome sequencing (WGS), RNA-seq and deep-scale proteomics; this study identified single copy amplification of the entirety of murine chromosome 7 (chr7) in 10 of the 11 tumors. We previously identified Gab2 as one relevant progression gene on chr7. However, while Gab2 overexpression significantly accelerates AML development in these mice, amplification of chr7 was still observed in 5 of 9 tested tumors despite retroviral overexpression of Gab2. These results suggest that additional gene(s) on this region may also be relevant.

Using Npm1c-driven murine AMLs with partial amplification of chr7 (generated in our lab and others), we identified a 4.6 Mbp minimally amplified region on chr7. We then used RNA expression and literature review to select additional candidate genes in this region for analysis, including Nup98, Ppme1, Inppl1 and P2ry2. We created a pool of murine stem cell virus (MSCV)-based retroviral vectors to overexpress each candidate in pre-leukemic Dnmt3aR878H/+ x Npm1cA/+ hematopoietic stem and progenitor cells (HSPCs), and transplanted the transduced cells into recipient mice. All engrafted mice developed AML in <5 months. WGS and RNA-sequencing identified expression of the Nup98-IRES-mCherry retroviral construct in all 10 tumors tested; median Nup98 RNA expression was increased 2.18-fold in these tumors compared to the mAMLs without retrovirus.

We next tested whether Nup98 overexpression alone could accelerate development of AML in this model. We used MSCV-based retroviruses to transduce pre-leukemic Dnmt3aR878H/+ x Npm1cA/+  HSPCs with one of four pairs of constructs: 1) Nup98-IRES-mCherry + Gab2-IRES-eGFP; 2) Nup98-IRES-mCherry + IRES-eGFP; 3) IRES-mCherry + Gab2-IRES-eGFP; and 4) IRES-mCherry + Gab2-IRES-eGFP. Each of these 4 sets of transduced cells was transplanted into 10 recipient mice. We observed that overexpression of Nup98-IRES-mCherry + Gab2-IRES-eGFP accelerated the development of AML, compared to IRES-mCherry + Gab2-IRES-eGFP (p = 0.017; median 4.2 vs 6.5 months).

We next reevaluated our previously published proximity labeling data (Kramer et al., Blood 2022), using either mutant NPM1cA or wildtype NPM1 fused to the TurboID biotin ligase, expressed in primary murine bone marrow HSPCs. Indeed, we observed a physical interaction between NUP98 and mutant NPM1cA protein, but no interaction was observed with wildtype NPM1. Previously, we reported several proteins that showed physical interactions with NPM1c, and that displayed evidence of post-transcriptional regulation of protein abundance, both in human patient AML samples and in murine AML samples. Using our published deep-scale proteomics data for this mAML model, we observed that NUP98 shows decreased protein abundance in mAML samples, compared to pre-leukemic mouse bone marrow, despite no changes in RNA abundance. This pattern of post-transcriptionally decreased protein abundance and physical interaction with NPM1c was observed for several nuclear pore proteins, including NUP214, NUP54, NUP188 and NUP358. The mechanism underlying this finding, and the functional consequences, remain to be investigated.

In summary, a well-established mouse model of AML driven by mutations in Dnmt3a and Npm1 provides in vivo evidence of cooperativity between wildtype Nup98 and mutant Npm1c, and establishes that expression levels of Nup98 can influence its ability to cooperate with Npm1c.
Michael Harris Kramer, MD PhD: No relevant conflicts of interest to declare.